Squarepoint
AMLX icon

Squarepoint’s Amylyx Pharmaceuticals AMLX Stock Holding History

Squarepoint’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.6M Buy
114,877
+38,315
+50% +$539K ﹤0.01% 2377
2025
Q4 		$925K Buy
+76,562
New +$1.04M ﹤0.01% 2685
2025
Q3 		– Sell
-40,643
Closed -$261K – 4331
2025
Q2 		$261K Sell
40,643
-35,206
-46% -$171K ﹤0.01% 3790
2025
Q1 		$269K Buy
75,849
+565
+0.8% +$2.01K ﹤0.01% 3817
2024
Q4 		$285K Buy
75,284
+27,279
+57% +$128K ﹤0.01% 4192
2024
Q3 		$156K Sell
48,005
-224,571
-82% -$505K ﹤0.01% 3772
2024
Q2 		$518K Buy
272,576
+113,267
+71% +$220K ﹤0.01% 3050
2024
Q1 		$452K Buy
159,309
+125,859
+376% +$1.65M ﹤0.01% 3119
2023
Q4 		$492K Sell
33,450
-6,550
-16% -$100K ﹤0.01% 3013
2023
Q3 		$732K Sell
40,000
-5,810
-13% -$123K ﹤0.01% 2531
2023
Q2 		$988K Sell
45,810
-45,916
-50% -$1.24M ﹤0.01% 2171
2023
Q1 		$2.69M Buy
91,726
+51,726
+129% +$1.8M 0.01% 1238
2022
Q4 		$1.48M Sell
40,000
-1,792
-4% -$63.6K 0.01% 1555
2022
Q3 		$1.18M Buy
+41,792
New +$1.04M 0.01% 1653
2022
Q2 		– Sell
-15,000
Closed -$193K – 2850
2022
Q1 		$193K Buy
+15,000
New +$339K ﹤0.01% 2488

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Squarepoint's AMLX Position: Q1 2026 in Review

Squarepoint increased its Amylyx Pharmaceuticals (AMLX) stake by 50% in Q1 2026, buying an estimated $539K and bringing the position to 114,877 shares worth $1.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2377.

Squarepoint first reported a position in AMLX in Q1 2022 and has held it in 15 quarters since. The position peaked at $2.69M in Q1 2023. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Squarepoint held 114,877 shares of Amylyx Pharmaceuticals worth $1.6M as of Q1 2026.
  • Squarepoint bought 38,315 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $539K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2377 holding.
  • Squarepoint first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 15 quarters since.
  • Squarepoint's Amylyx Pharmaceuticals position peaked at $2.69M in Q1 2023.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.